Paul Christian Schulze

Lipid Use and Misuse by the Heart.

Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.

MicroRNAs in heart failure: Non-coding regulators of metabolic function.

Exercise capacity, physical activity, and morbidity.

Specifics of fetuin-A levels in distinct types of chronic heart failure.

Arginase Inhibition Reverses Monocrotaline-Induced Pulmonary Hypertension.

Serum exosomal protein profiling for the non-invasive detection of cardiac allograft rejection.

The Lactate/Albumin Ratio: A Valuable Tool for Risk Stratification in Septic Patients Admitted to ICU.

Increased Serum Levels of Fetal Tenascin-C Variants in Patients with Pulmonary Hypertension: Novel Biomarkers Reflecting Vascular Remodeling and Right Ventricular Dysfunction?

MicroRNA-195 Regulates Metabolism in Failing Myocardium Via Alterations in Sirtuin 3 Expression and Mitochondrial Protein Acetylation.

Therapeutic options in advanced heart failure.

What's new in heart failure therapy 2018?

Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome.

Correction to: Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome.

Lipid in the midst of metabolic remodeling - Therapeutic implications for the failing heart.

Metabolomic profiling of patients with high gradient aortic stenosis undergoing transcatheter aortic valve replacement.

Ketone bodies for the starving heart.

Psychosocial factors, mental health, and coordination capacity in patients with heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction.

Increased cholesterol absorption is associated with In-stent-restenosis after stent implantation for stable coronary artery disease.